Nebulized mRNA‐Encoded Antibodies Protect Hamsters from SARS‐CoV‐2 Infection

Autor: Daryll Vanover, Chiara Zurla, Hannah E. Peck, Nichole Orr‐Burks, Jae Yeon Joo, Jackelyn Murray, Nathan Holladay, Ryan A. Hobbs, Younghun Jung, Lorena C. S. Chaves, Laura Rotolo, Aaron W. Lifland, Alicia K. Olivier, Dapeng Li, Kevin O. Saunders, Gregory D. Sempowski, James E. Crowe Jr., Barton F. Haynes, Eric R. Lafontaine, Robert J. Hogan, Philip J. Santangelo
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Advanced Science, Vol 9, Iss 34, Pp n/a-n/a (2022)
Druh dokumentu: article
ISSN: 2198-3844
70263213
DOI: 10.1002/advs.202202771
Popis: Abstract Despite the success of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccines, there remains a clear need for new classes of preventatives for respiratory viral infections due to vaccine hesitancy, lack of sterilizing immunity, and for at‐risk patient populations, including the immunocompromised. While many neutralizing antibodies have been identified, and several approved, to treat COVID‐19, systemic delivery, large doses, and high costs have the potential to limit their widespread use, especially in low‐ and middle‐income countries. To use these antibodies more efficiently, an inhalable formulation is developed that allows for the expression of mRNA‐encoded, membrane‐anchored neutralizing antibodies in the lung to mitigate SARS‐CoV‐2 infections. First, the ability of mRNA‐encoded, membrane‐anchored, anti‐SARS‐CoV‐2 antibodies to prevent infections in vitro is demonstrated. Next, it is demonstrated that nebulizer‐based delivery of these mRNA‐expressed neutralizing antibodies potently abrogates disease in the hamster model. Overall, these results support the use of nebulizer‐based mRNA expression of neutralizing antibodies as a new paradigm for mitigating respiratory virus infections.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje